Lexaria Bioscience
LEXX
15 hedge funds and large institutions have $803K invested in Lexaria Bioscience in 2026 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 16 closing their positions.
353% more capital inflows, than outflows
Capital inflows: $1.39M | Capital outflows: $308K
8.86% more ownership
Funds ownership: 6.65% → 15.51% (+8.9%)
48% less funds holding
Funds holding: 29 → 15 (-14)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
88% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$1.31M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$73.6K |
| 3 |
Tower Research Capital (TRC)
New York
|
+$13.4K |
| 4 |
Danske Bank
Copenhagen K,
Denmark
|
+$8 |
| 5 |
Vanguard Global Advisers
Malvern,
Pennsylvania
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$87.9K |
| 2 |
HRT Financial
New York
|
-$36K |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$35.4K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$22.3K |
| 5 |
State Street
Boston,
Massachusetts
|
-$22K |
LEXX Hedge Fund Activity: Q3 2026 in Review
15 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q3 2026, worth a combined $803K — down 13% from $924K a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of LEXX and 2 opened new positions — a net loss of 14 holders — while 8 trimmed existing stakes and 3 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.31M. The largest seller was Citadel Advisors, exiting entirely with an estimated $87.9K sold.
- 15 institutional investors held Lexaria Bioscience (LEXX) as of Q3 2026, down from 29 in Q2 2026.
- Funds reported $803K of Lexaria Bioscience stock for Q3 2026, down 13% quarter-over-quarter.
- 2 funds opened new Lexaria Bioscience positions in Q3 2026 and 16 closed out, a net change of -14 holders.
- The largest Lexaria Bioscience buyer in Q3 2026 was Armistice Capital, an estimated $1.31M added.
- The largest Lexaria Bioscience seller in Q3 2026 was Citadel Advisors, an estimated $87.9K sold.
Based on aggregated 13F filings for Q3 2026.